Latest news

• GSK sells eczema and psoriasis drug to Dermavant for £250m

  The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... Meanwhile, in atopic dermatitis, Regeneron and Sanofi’s IL4/IL-13 inhibitor Dupixent (dupilumab)

• AZ’s Fasenra hit by COPD trial failure

  Nucala was the first IL-5 inhibitor to reach the market in 2015, and made £344m ($465m) in sales last year. ... IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic

• NICE rejects Sanofi’s Dupixent for atopic dermatitis at first call

  Despite the confidential discount on Dupixent’s list price of £1, 264.89 per pack of two syringes of the IL-4 and IL-13 inhibitor - developed with Regeneron - the cost

• AZ gets EMA green light for severe asthma drug Fasenra

  AstraZeneca has picked up an approval in the EU for its interleukin-5 inhibitor Fasenra in severe asthma, mirroring its US approval in this indication last November. ... Prospects for IL-13 inhibitor tralokinumab look terminal after three failed

• AZ prices severe asthma drug Fasenra below competition

  The US FDA has approved AstraZeneca’s interleukin-5 inhibitor Fasenra for severe asthma, setting up a fight in the market with rival drugs from GlaxoSmithKline and Teva. ... Prospects for IL-13 inhibitor tralokinumab look rocky after two failed